NCT05557123Completed
Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)
The ReInforcement of Adherence Via Self-monitoring App Orchestrating Biosignals and Medication of RivoXaban in Patients With Atrial Fibrillation and Co-morbidities: Randomised Control Study(RIVOX-AF Study)
Source: ClinicalTrials.gov · Last updated 19 May 2026
Brief summary (registry, in English)
RIVOX-AF study is a prospective, multicenter, randomized controlled study in which patients with AF are allocated to medication-app group or conventional treatment group. The App based feed-back algorithm will provide the patients with check taking drug or reminding of taking drug.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 637 (actual)
- First submitted
- 20 Sept 2022
- Start date
- 10 Mar 2022
- Primary completion date
- 16 Dec 2025
- Lead sponsor
- Seoul National University Bundang Hospital
- Diseases
- Atrial fibrillation
- NCT number
- NCT05557123
What you commit to
- Study type: Interventional
- Participants enrolled: 637
- From 10 Mar 2022 to the primary completion date, 16 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Not eligible for study due to legal or psychiatric problem
Lab values
- creatinine clearance \<15ml/min
Other
- moderate or severe mitral stenosis
- mitral valve operation history
- current alcohol abuse or alcohol abus history
- enrolled other clinical study within 4 weeks
- declined to enroll the study
Who the study is looking for
- Patients with AF aged 19 years or older with one or more comorbidities including heart failure, myocardial infarction, stable angina, hypertension or diabetes mellitus (Patients can be enrolled 3 months after myocardial infarction or percutaneous coronary intervention).
- patients who already took or plan to take rivoxban
- patients who able to use smart phone
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Bundang Hospital Coordinator of this site? Confirm its status | Seongnam | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.